N/A N=655 Aortoiliac Stenosis in Kidney Transplantation
Aorto-Iliac Arterial Stenosis · Peripheral Arterial Disease · Kidney Transplant Failure
Primary: Patient Survival — 322; 48; 6 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=31 Combination Drug Therapy Followed by Single Drug Steroid Free Therapy to Prevent Organ Rejection in Kidney Transplantation
Kidney Transplantation
Primary: The Rate of Allograft Rejection — 0; 0 participants
Phase 2 N=5 Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection
Kidney Transplantation · Kidney Failure, Chronic
Primary: Number of Participants Successfully Withdrawn Off of Immunosuppressant Medication for 104 Weeks — 3 participants
Phase 2 N=7 Study of Islet Transplantation in Type 1 Diabetic Kidney Transplant Recipients
Diabetes Mellitus, Type I
Primary: Insulin Independence With Both an HbA1c ≤ 6.5% and no Severe Hypoglycemic Events at 1 Year After the First Islet Transplant or a Reduction in HbA1c of at Least 1 Point…
N/A N=60 Hyperglycemia in Renal Transplantation
Diabetes · End Stage Renal Disease
Primary: Incidence of Poor Graft Function After Kidney Transplant — 13; 22 Participants
Phase 2 N=12 Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection
Kidney Failure
Primary: Serum Creatinine Concentration — 112 umol/L
Phase 2 N=7 Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation
Diabetes Mellitus, Type 1
Primary: Insulin Independence. — 2 Participants
N/A N=42 Improving Adherence in Nonadherent Kidney Transplant Patients
Medication Adherence · Kidney Transplantation
Primary: Change in Number of Patients Being Adherent/Non-aherent After the Intervention — 15; 30; 34; 35 Participants
N/A N=167 Transplant Navigator Intervention to Overcome Barriers to Kidney Transplantation
End Stage Renal Disease
Primary: Number of Steps Completed in Transplant Process — 1.0; 2.8 steps per participant
Phase 2 N=62 Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients
End Stage Renal Disease
Primary: Number of Subjects Cured — 62 Participants
N/A N=30 DBS for Home Monitoring in Children With Kidney Transplantation
Kidney Disease
Primary: Variability of Tacrolimus Blood Levels Measured by DBS Over Time — 2.635 ng/ml
Phase 4 N=11 Prospective Pilot Study of Pre-Transplant Thymoglobulin Administration in Living Donor Renal Transplant Recipients
Renal Transplant Rejection · Transplants and Implants
Primary: Composite End Point of Acute Rejection, Graft Loss or Patient Death — 1; 1; 0; 0 participants
N/A N=90 Vitamin D Replacement After Kidney Transplant
Kidney Transplantation · Vitamin D Deficiency
Primary: Compare Efficacy and Safety of Two Vitamin D Supplements of These Doses in Normalizing Vitamin D Concentrations. — 8; 29 ng/ml
Phase 2 N=290 Effects of Inhibiting Early Inflammation in Kidney Transplant Patients
Kidney Transplant
Primary: The Difference Between the Mean eGFR (Modified MDRD) in the Experimental vs. Control Groups. — 52.45; 57.35 mL/min/1.73m2 — p=0.099
N/A N=105 Conventional Laparoscopic Versus Laparoendoscopic Single Site Donor Nephrectomy in Living Donor Kidney Transplantation
Living Donors · Nephrectomy · Kidney Transplantation
Primary: The Primary End Point of the Study Was the Mean/Median Number of Days Postsurgery Required for Each Group to Return to 100% Functioning Capacity. — 43; 45 days
Phase 2 N=40 Belatacept Post Depletional Repopulation to Facilitate Tolerance
Organ Transplantation
Primary: Number of Patients Successfully Withdrawn From Oral Immunosuppression — 12; 7 Participants
Phase 2 N=26 Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross Match Living Donor Kidney Transplant
Kidney Transplant
Primary: Number of Subjects With Antibody-Mediated Rejection (AMR) in the First 3 Months After Living Donor Kidney Transplantation — 2 Participants
Phase 4 N=180 Improved Induction and Maintenance Immunosuppression in Kidney Transplantation
End-stage Renal Disease
Primary: Chronic Allograft Nephropathy (Cumulative Calcineurin-inhibitor Nephrotoxicity/Transplant Nephropathy) Per Protocol Surveillance Kidney Biopsies (Banff Grading…
N/A N=56,332 Disparities in National Kidney Allocation Policy
Kidney Disorders
Primary: Proportion of Incident Patients Waitlisted — 1.39; 1.33; 1.25; 1.30 adjusted mean proportion of patients
Phase 4 N=10 Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors
End Stage Renal Disease · Hepatitis C
Primary: Viral Response as Assessed by Number of Participants With Undetectable Hepatitis C RNA — 10 Participants
Phase 2 N=2 Renal Allograft Tolerance Through Mixed Chimerism
End Stage Renal Disease
Primary: Successful Withdrawal of Immunosuppressive Therapy — 2 Participants
N/A N=422 Increasing Live Donor Kidney Transplantation Through Video-based Education and Mobile Communication
End-stage Renal Disease · Chronic Kidney Diseases
Primary: Living Donor Inquiry — 16.0; 18.6 Percentage of participants — p=0.507
Phase 4 N=20 Desensitization in Kidney Transplantation
HLA Sensitization
Primary: Number of Living Donor Transplant Candidates That Are Transplanted — 19 participants
N/A N=104 IV Insulin Protocol in Diabetes and Renal Transplantation
Kidney Transplantation · Diabetes · Hyperglycemia
Primary: Delayed Graft Function — 8; 12 participants
N/A N=135 Effects of Personalized Physical Rehabilitation in Kidney Transplant Recipients
Kidney Transplant
Primary: Employment Status — 21; 2 Participants
Phase 1 N=2 Renal Allograft Tolerance Through Mixed Chimerism (Belatacept)
Kidney Failure, Chronic · Renal Insufficiency
Primary: Number of Participants With Successful Withdrawal of Immunosuppression — 2 Participants
Phase 1 N=16 Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney Transplantation
Kidney; Complications, Allograft
Primary: Baseline eGFR (Estimated Glomerular Filtration Rate) — 30.04; 30.04 mL/min/1.73 m2
N/A N=2 Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease
Multiple Myeloma · Amyloidosis
Primary: Number of Participants Without Renal Allograft Rejection at 6 Months Post-transplant — 1 Participants
Phase 4 N=6 Switch From Calcineurin Inhibitor to Belatacept in Pancreas Transplant Recipients
Nephrotoxicity
Primary: Change From Baseline in Serum Estimated Glomerular Filtration Rate (eGFR) — 2.25 ml/min/1.73m2
N/A N=50 Perioperative Aminophylline to Improve Early Kidney Function After a Kidney Transplant
Function of Renal Transplant
Primary: Calculated Estimated Glomerular Filtration Rate (eGFR) — 67.39; 80.48 ml/min/1.73m2 — p=0.32